ImaCor wants the ICU to stop guessing about the heart.

A patient is crashing in an intensive care unit. Blood pressure is sliding. The team has a choice that has to be made in seconds: more fluid, or less. Get it wrong in either direction and the patient gets worse. For decades, this decision has been made on inference - numbers off a monitor that hint at what the heart might be doing. ImaCor's answer is blunter: stop hinting. Look at the heart.

That is the whole company. ImaCor, Inc., a roughly 19-person outfit in Garden City, New York, builds the world's first and only hemodynamic transesophageal echocardiography platform - hTEE, if you want the clinical shorthand. Translated: a small, swallowed ultrasound probe that gives the bedside team a live, moving picture of the heart's filling and squeeze, on demand, over days. Not a proxy. The actual chambers, in motion.

It is a small company solving a problem that is anything but small. And it has been at it, patiently, since before most people had heard the word "hemodynamic."

The heart is the one organ everyone treats and almost no one watches.

Here is the awkward truth of critical care: the most consequential decisions revolve around an organ the team usually cannot see. The traditional tools - the pulmonary artery catheter threaded through the heart, the pressure waveforms, the lab values - are all clever ways of guessing at what the heart is doing from the outside. They measure shadows and infer the object.

Echocardiography, the obvious fix, was for years a scheduled event. You called a cardiologist, wheeled in a cart, captured a snapshot, and the cart left. The heart, of course, did not agree to stop changing between visits. A patient can be over-filled at noon and bone-dry by three, and the cart was long gone.

So the bedside team did what it had always done: it inferred. It treated numbers instead of the heart that produced them. Most of the time that worked. The trouble was the times it didn't - and in an ICU, the times it doesn't are the times that matter most.

Two cardiologists and a scientist decided the cart should never leave.

In 2009, Scott Roth, M.D. and Steven Evans, M.D. - cardiologists who had watched the inference game from the inside - teamed up with scientist Harold Hastings, Ph.D. The bet was specific and a little stubborn: what if the echo probe were small enough, and gentle enough, to simply stay in the patient? Not for a snapshot. For days.

That meant inventing a probe nobody had built: miniaturized, disposable, comfortable enough to remain indwelling, and good enough to trust. It also meant a second, quieter bet - that an ordinary ICU team, not just a visiting cardiologist, could be trained to capture and read the views. Make the tool simple, and the heart becomes everyone's to watch.

Investors took the bet too. A $5.45M Series A closed in February 2009, with Johnson & Johnson Development Corporation and WFD Ventures backing the idea that the ICU deserved a live feed of the heart.

A probe that stays, a method anyone can learn, and a handheld that fits in a coat.

Strip away the acronyms and ImaCor sells three connected things. The first is the ClariTEE probe - the miniaturized, disposable centerpiece, cleared to remain in a patient for up to 72 hours. The second is the Zura imaging system, the bedside platform that turns the probe's signal into a readable picture of preload, contractility, and right- and left-ventricular size and function. The third, newest, is the Zura Handheld - built with Clarius Mobile Health and cleared by the FDA in 2022 as the world's first handheld TEE system, all 22 ounces of it.

Caption: A 22-ounce device that images the inside of a beating heart weighs less than the average hardcover novel. The novel, admittedly, is easier to read.

Seeing the heart changed what doctors did next.

A nicer picture is a gimmick unless it changes a decision. ImaCor's case rests on the claim that it does. In reported ICU use, hemodynamic ultrasound made a direct, therapeutic impact in 66% of patients and improved hemodynamics in 80%. Put plainly: most of the time the team looked, what they saw was enough to change the plan.

The proof isn't only in the data. It's in the company ImaCor keeps. The Clarius partnership turned a cart-bound technology into something a clinician carries. The American Heart Association brought ImaCor into its Innovators' Network. The Octane Cardiovascular Tech Summit handed it a Judge's Choice award in 2023. And more than 15,000 patients have now been watched, in real time, by a probe that simply refused to leave the room.

Replace inference with a view.

ImaCor states its purpose without much poetry: enable clinicians to optimize cardiac performance with direct cardiac visualization during critical care. Underneath the clinical phrasing is a quiet rebellion against guesswork. The ICU has always been a place of educated estimates. ImaCor's mission is to shrink the "estimate" part until the team is treating a heart it can actually watch.

That is why the training matters as much as the hardware. A probe only democratizes the heart if ordinary teams can use it. The hTEE method exists so the view isn't locked behind a specialist's schedule - so that at 3 a.m., the people already in the room can look.

The window is getting smaller, lighter, and harder to argue with.

The trajectory is clear in the products. A cart became a bedside system became a 22-ounce handheld. Each step put the heart in front of more clinicians, in more rooms, with less ceremony. The company's keywords now include AI-driven imaging and clinical decision support - signs that the next move is not just showing the heart, but helping interpret it. The fewer specialists a live cardiac view requires, the more ICUs can afford to stop guessing.

There are honest caveats. ImaCor is small, the market is conservative, and convincing hospitals to adopt anything new is a years-long campaign measured in clearances and peer-reviewed papers. But the direction of travel is hard to dispute: critical care is moving from inference toward visualization, and ImaCor has spent fifteen-plus years pointing the way.

So return to that room. 3 a.m., a patient sliding, the team with seconds to choose. In the old version, they read the shadows and made their best guess. In ImaCor's version, someone glances at a screen and sees the heart - too full, or too empty - and the choice stops being a guess. That is the entire ambition of this small New York company: to turn the hardest decision in the ICU into something you can simply look at.